Cerevel Therapeutics, co-founded by Pfizer, is set to undertake a reverse merger with Nasdaq-listed Arya II in a deal that will give Cerevel a market cap of $1.3bn.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Thrive Earlier Detection, the developer of an early cancer screening blood test invented at JHU and backed by Exact Sciences and Blue Cross and Blue Shield Association, has raised $257m in series B funding.

Thrive Earlier Detection, the developer of an early cancer screening blood test invented at JHU, has raised $257m in series B funding.

Sema4, spun out of Icahn School of Medicine, has achieved a valuation of more than $1bn following a $121m series C round.

Mount Sinai Health System spinoff Sema4 has achieved a valuation of more than $1bn following a $121m series C round that featured all existing external shareholders.

Heal has entered into a strategic partnership with Humana that includes a $100m investment from the corporate and will support an expansion into additional US cities.

Nan Fung Life Sciences formed part of a consortium of new and existing backers that injected $71m into hearing aid manufacturer Eargo.

Osaka University Venture Capital was among the investors in a series D round for Kyorin University-founded cancer treatment developer J-Pharma.

Funding for HUJ spinouts remained stable during the first six months of 2020 as the Israeli VC sector showed signs of resilience amid Covid-19.